People · Operator
Named in public records as an officer, director or promoter · active 2021–2021 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| bluebird bio, Inc. | — | Biotechnology | Series C | $187.5M | $1.9B | 2021 |
Nick S. Leschly at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Nick S. Leschly on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Steven Gillis | 1 | 23 |
| Robert Tepper | 1 | 7 |
| Daniel S. Lynch | 1 | 6 |
| Nick Leschly | 1 | 5 |
| Chip Baird | 1 | 4 |
| James A. Geraghty | 1 | 3 |
| William R. Sellers | 1 | 2 |
| Geert-Jan Mulder | 1 | 2 |
| Denice R. Torres | 1 | 2 |
| Wendy S. Dixon | 1 | 1 |
| Geert-Jan A. Mulder | 1 | 1 |
| Axel Polack | 1 | 1 |
| Jeffrey T. Walsh | 1 | 1 |
| John M. Maraganore | 1 | 1 |
| Ramy S. Ibrahim | 1 | 1 |
| Jason Cole | 1 | 1 |
| Mark R. Vachon | 1 | 1 |
| John S. Agwunobi | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.